RT Journal Article
SR Electronic
T1 Genetic analysis of lung cancer reveals novel susceptibility loci and germline impact on somatic mutation burden
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.26.21254132
DO 10.1101/2021.04.26.21254132
A1 Gabriel, Aurélie AG
A1 Atkins, Joshua R
A1 Penha, Ricardo CC
A1 Smith-Byrne, Karl
A1 Gaborieau, Valerie
A1 Voegele, Catherine
A1 Abedi-Ardekani, Behnoush
A1 Milojevic, Maja
A1 Olaso, Robert
A1 Meyer, Vincent
A1 Boland, Anne
A1 François Deleuze, Jean
A1 Zaridze, David
A1 Mukeriya, Anush
A1 Swiatkowska, Beata
A1 Janout, Vladimir
A1 Schejbalová, Miriam
A1 Mates, Dana
A1 Stojšić, Jelena
A1 Ognjanovic, Miodrag
A1 the ILCCO consortium
A1 Witte, John S
A1 Rashkin, Sara R
A1 Kachuri, Linda
A1 Hung, Rayjean J
A1 Kar, Siddhartha
A1 Brennan, Paul
A1 Sertier, Anne-Sophie
A1 Ferrari, Anthony
A1 Viari, Alain
A1 Johansson, Mattias
A1 Amos, Christopher I
A1 Foll, Matthieu
A1 McKay, James D
YR 2021
UL http://medrxiv.org/content/early/2021/10/12/2021.04.26.21254132.abstract
AB Germline genetic variants are involved in lung cancer (LC) susceptibility. Previous genome-wide association studies (GWAS) have implicated genes involved in smoking propensity and DNA repair but further work is required to identify additional LC susceptibility variants and to investigate LC disease development dynamics.We have undertaken a family history-based genome-wide association (GWAx) study of LC, analysing 48,843 European cases with a parent/sibling with LC compared to 195,387 controls from the UK Biobank. This was meta-analysed with previously described LC GWAS results. We performed Polygenic Risk Scores (PRS) analyses and further evaluated the PRS influence on the somatic environment in exome (N=736) and genome sequencing (N=61) profiled cohorts.Eight novel loci were identified including DNA repair genes (CHEK1, MDM4), metabolic genes (CYP1A1) and variants that were also associated with smoking propensity, such as both subunits of the neuronal α4β2 nicotinic acetylcholine receptor (CHRNA4 and CHRNB2). PRS analysis demonstrated that variants related to eQTLs and/or smoking propensity are enriched for susceptibility variants, including variants below genome-wide significant threshold. PRS of LC variants related to smoking propensity were associated with somatic mutation burden in two case cohorts, with individuals with higher polygenic genetic risk having increased numbers of somatic mutations in their lung tumours.This study has expanded the number of susceptibility loci linked with LC and provided insights into the molecular mechanisms by which these susceptibility variants contribute to the development of lung cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Institut National du Cancer (INCa) (GeniLuc 2017-1-TABAC-03-CIRC-1 - [TABAC 17 022], NIH/NCI, Integral NIH 5U19CA203654-03, Cancer Research UK [grant number C18281/A29019], the France Genomique National infrastructure, funded as part of the Investissements d'Avenir program managed by the Agence Nationale pour la Recherche (contract ANR-10-INBS-09). Christopher Amos is a Research Scholar of the Cancer Prevention Institute of Texas and supported by RR170048.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study contains a meta-analysis from already published data. The lung cancer cohort in McKay 2017 and the UK Biobank in Bycroft 2018. In the replication cohort for the somatic PRS, the GeniLuc cohort has not previously been publish. Ethnics for the GeniLuc cohort was reviewed by the IARC ethnics board (IARC IRB 12-05) and approved on 28th of April 2016.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available on request - PRS panels and weights are within the supplementary data